Stemline Therapeutics (STML) Earning Somewhat Favorable Press Coverage, Accern Reports

News headlines about Stemline Therapeutics (NASDAQ:STML) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Stemline Therapeutics earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.8991749908761 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Stemline Therapeutics (NASDAQ STML) opened at 12.45 on Friday. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $14.60. The firm’s 50-day moving average is $10.44 and its 200-day moving average is $9.04. The company’s market capitalization is $292.01 million.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.18). The company had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.30 million. Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%. Equities research analysts predict that Stemline Therapeutics will post ($2.56) EPS for the current year.

Several research analysts have recently weighed in on STML shares. HC Wainwright set a $34.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. BidaskClub upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, July 19th. ValuEngine downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Finally, Zacks Investment Research downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company. Stemline Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $32.60.

ILLEGAL ACTIVITY WARNING: “Stemline Therapeutics (STML) Earning Somewhat Favorable Press Coverage, Accern Reports” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply